Skip to main content
Equibles
STOK logo

STOK · Stoke Therapeutics, Inc. · Metrics

Track STOK — free

Use STOK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STOK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$26.61 +1.79 (+7.21%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$1.60B
Shares
64.53M
Volume · Oct 20 2.46M Avg daily vol (3M) 903.63K

STOK metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$26.61
Market cap
$1.60B

Price action

20 metrics
Price change (1W)
+18.3%
Price change (30D)
-5.1%
Price change (3M)
-7.6%
Price change (6M)
-25.3%
Price change (YTD)
-16.2%
Price change (1Y)
-23.2%
Trailing year
Price change (5Y)
+17.6%
52-week high
$38.35
52-week low
$22.37
Change from 52-week high
-30.6%
Change from 52-week low
+19.0%
Annualized volatility
57.1%
Annualized volatility (3M)
49.2%
Beta
0.9
RSI (14D)
53.4
Price vs SMA 50
-6.4%
Price vs SMA 200
-14.7%
Avg volume (3M)
903,625
Relative volume
2.7
Average dollar volume
$25.92M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.53M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
58.1×
reciprocal yield 1.7%
P / book
4.6
reciprocal yield 21.6%
FCF yield
-11.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
—
Operating margin
-809.7%
Trailing 12 months
Net margin
-753.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$223.38M
Net income (TTM)
−$207.90M
Trailing 12 months
Diluted EPS (TTM)
$-3.34
FCF margin
-654.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.44
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.59
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.34
Operating cash flow per diluted share (TTM)
$-2.84
Free cash flow per diluted share (TTM)
$-2.88
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
$2.71
Stock compensation per diluted share (TTM)
$0.60
Book value per share
$5.98

Growth

11 metrics
Revenue growth YoY
-32.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$27.59M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+13.1%
Year over year · more shares
Revenue CAGR (3Y)
+145.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-60.2%
Return on assets
-52.8%
Debt / equity
—
Current ratio
7.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$180.68M
Quick ratio
7.7
Interest coverage
-4,963.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$110.00M
Latest balance sheet
Cash & equivalents
$110.00M
Total assets
$393.97M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$177.99M
Capital expenditures (TTM)
$2.69M
R&D (TTM)
$168.56M
SG&A (TTM)
$82.40M
Stock compensation (TTM)
$37.44M
R&D / revenue
611.0%
Stock compensation / revenue
135.7%

Ownership (13F)

9 metrics
13F filers
198
13F filer change QoQ
0
Institutional ownership
118.2%
Conviction holders (share of 13F filers)
2.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+6.6%
Holder tenure
14.3
Price vs estimated holder cost
+60.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.4%

Short interest

3 metrics
Short interest
17.8%
Latest settlement · 10.2 days to cover
Days to cover
10.2d
Short-squeeze score
89 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.07M
Insider-sentiment score
27 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1623526 CUSIP 86150R107 13F (30d) 12 filings 12 filers Visit website Investor relations